Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention"

NCT05443555 is registered in ClinicalTrials.gov with Boston Medical Center as lead sponsor.

NCT NCT05443555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05443555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention"
Lead sponsor
Boston Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 20, 2023
Completion date
June 30, 2027
Enrollment
220 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heavy drinking, hiv